Pleno, a San Diego-based company, has launched an early-access program for its Raptor multiomics biomarker detection platform, positioning for a full commercial debut by 2026 or 2027. The technology employs circularizable probes to simultaneously profile tens of thousands of biomarkers across genetic and epigenetic domains, addressing a niche between sequencing and microarray methods. Initial users like Slopes Bio have validated Raptor’s efficiency, cost-effectiveness, and sample throughput, heralding a novel solution for moderate-sized clinical gene panels.